

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 9/00	A2	(11) International Publication Number: WO 00/25743 (43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/23993 (22) International Filing Date: 2 November 1999 (02.11.99) (30) Priority Data: 09/185,944 4 November 1998 (04.11.98) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). (72) Inventors: SHIH, Chung; 2798 E. Amberwick Lane, Sandy, UT 84093 (US). KENNEDY, Thomas, J.; 5492 Kennedy Drive, Waunakee, WI 53597 (US). KNIGHT, Peter, James; 1826 Gary Road, Warren, NJ 08886 (US). ROBINS, Daniel, S.; Apartment 3B, 77 East 12th Street, New York, NY 10003-5003 (US). SHAO, Zezhi, Jesse; 68 Patriot Hill Drive, Basking Ridge, NJ 07920 (US). (74) Agents: KALYANARAMAN, Palaiyur, S. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: IMPROVED GROWTH STIMULANT COMPOSITIONS		
(57) Abstract An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

IMPROVED GROWTH STIMULANT COMPOSITIONS

FIELD OF THE INVENTION

5 The invention relates generally to veterinary pharmaceutical compositions and formulations that control the release of the active compound therein to the animal. More specifically, the present invention discloses actives in a dual formulation that stimulates growth and weight gain in domestic animals.

10

BACKGROUND OF THE INVENTION


 There have been many recent advances in the veterinary sciences and veterinary pharmacology that have resulted in the growth and development of larger, healthier and heartier, bovine, porcine, ovine
15 and equine species. Particularly with respect to the bovine, ovine and porcine groups, the need to feed the world's population through the production of meat provides the impetus to raise domestic animals that grow as quickly and as large as possible.

 Anabolic agents, are widely used to promote the growth of cattle
20 and other domestic animals and stimulated growth promotion is desirable among the cattle farmers because it maximizes both rate of weight gain and the absolute amount of weight gain per average amount of food consumed, which is termed feed efficiency. Generally, steroids are supplied to the animal in the form of a bio-degradable or
25 non-biodegradable, implantable, time release pellet(s) which is injected under the skin using an implant device. These have been proven to be successful; however, the animals may have to be implanted 2-4 times during their growth period.

- 2 -

The implant devices used for the subcutaneous delivery of these steroid pellets consist of a housing in the shape of a pistol with a handle, a hollow needle for injecting the pellet into the body of the animal located at the front side of the housing, and a push-rod. The push-rod
5 can be slid into this hollow needle and is supported in the housing so as to be displaceable longitudinally. A chamber is provided in the housing and is attached to the needle. A magazine containing the pellets is inserted and displaceable therein. A longitudinally displaceable press-back device (spring ejector) is arranged in the housing parallel to the
10 push-rod and hollow needle in the housing. The push-rod and press-back device are moved by a driving mechanism which is similarly provided in the housing and which can be set in motion by the operating lever (trigger) fastened to the handle. This engages the driving mechanism and press-back device via a toothed segment
15 coupled with the operating lever and a toothed wheel engaging the press-back device and push-rod. Such a device design is described, for example, in U.S. patent 5,514,101.

Zeranol (Formula I, CAS Registry Number: 26538-44-3) is an anabolic agent which has shown impressive results in the promotion



Formula I

20 of weight gain and growth in cattle. Zeranol, a resorcylic acid lactone derivative, has shown to be a positive influence on dynamic protein metabolism. However, during the growth and development of the cattle, current formulations containing zeranol or other such anabolic
25 agent must be administered at least twice over the 170 day growth and

- 3 -

development period for optimal results. Obviously, this necessitates bringing cattle in from the fields, reinjecting the implant and transporting them out again which is a laborious and time-consuming process.

5 It has been determined that zeranol and other anabolic agents provide the best growth and weight gain results when administered early on and throughout the animal's growth cycle. This would require a dual immediate-release/sustained-release formulation which has been hereinbefore not possible.

10 United States Patent No. 5,643,595 to Lewis discloses and claims a delivery system for veterinary growth promotants consisting of a biodegradable polymeric matrix that contains a steroid growth promotant and an antibiotic. The steroid growth promotant may consist of zeranol which is formulated within sustained-release microparticles
15 consisting of homopolymers or copolymers of lactic and/or glycolic acid. Other biodegradable polymers used in the sustained-release formulations include polycaprolactone, polydioxonene, polyorthoesters, polyanhydrides, waxes, casein and mixtures thereof.

20 United States Patent No. 5,427,796 also to Lewis discloses a method for increasing animal growth comprising the administration of an anabolic steroid such as zeranol in a biodegradable microparticle delivery system that releases the drug in a multiphasic manner. Drug delivery duration allegedly lasts up to 200 days. The same polymers are used in Lewis's other patents noted above and below.

25 United States Patent Nos. 5,419,910 and 5,288,496 to Lewis also disclose and claim a microparticulate sustained-release delivery system for promoting growth in animals. The microparticles are comprised of a biodegradable polymeric matrix such as poly-d,l-lactic acid, polyglycolic acid and the like. The microparticles separately encapsulate a steroid
30 growth promotant and an antibiotic. Zeranol, among other anabolic steroids, is disclosed as one of the useful actives that result in increased bulk weight and growth.

- 4 -

United States Patent No. 4,874,612 to Deasy discloses a multi-component implant for the sustained-release, long-term delivery of pharmaceutical agents to humans and animals for the treatment of vitamin deficiencies, hormone replacement therapy, cancer therapy, infection and the like. Preferably, the biodegradable polymers comprising the implants are used to deliver animal growth promotants which contain anabolic steroids such as zeranol as well as their combinations. The matrix used to make the implants consists of lactic acid/glycolic acid copolymers.

United States Patent No. 4,191,741 to Hudson *et al* discloses and claims polymeric implants for the long-term sustained-release of anabolic agents to ruminant animals. The steroids can be administered alone or in combination, one of which is estradiol. Zeranol is not specifically disclosed as one of these agents.

In fact, the use of biodegradable particles for the long-term, sustained-release of anabolic steroids and other pharmaceutical actives is known in the art. See for example, United States Patent Nos. 4,683,288; 4,677,191; 4,675,189; 4,542,025; 4,530,840; 4,489,055 and 4,389,330.

Unfortunately, not all of the prior art delivery systems enable zeranol to be administered in a way that maximizes the growth and weight gain potential that exists. Whereas zeranol and other anabolic agents must be administered two to four times during the growth phase of the animal, it would be most advantageous to provide a formulation that need only be administered once.

It is an object of the present invention to provide an anabolic implant formulation for increased growth and weight gain significantly greater than that achieved by animals given other steroid therapies and those given none at all. It is a further object of the present invention to provide an anabolic implant formulation that is given only once during the growth phase of the animal yet provides both immediate and sustained, long-term administration of the drug throughout the growth period for optimal growth and weight gain.

- 5 -

SUMMARY OF THE INVENTION

The above-noted objects and others are addressed by aspects of the present invention which provides a method and an anabolic implant
5 formulation for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in cattle. The inventive method comprises administering to the animal an implant composition (or implant as is commonly called) which comprises: (i) an immediate-release formulation containing an anabolic agent, and (ii) a controlled-
10 release formulation containing an anabolic agent with a controlled-release agent, wherein the immediate-release formulation and the controlled-release formulation cooperate to effect the desired stimulation of growth and weight gain. The immediate-release formulation and the controlled-release formulation may be
15 simultaneously administered, or one immediately followed by the other in quick succession in whichever order the administrator chooses, to the animal. Applicants have found that the inventive method of administering a dual formulation surprisingly results in growth and weight gain in the animal much higher than when either formulation
20 (i) or (ii) is implanted without the other.

The present invention further discloses a method of preparing the above-noted dual formulation, an anabolic implant composition comprising a dual formulation, as well as a method for stimulating growth and weight gain in animals using such compositions.
25

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, this invention discloses a method for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in animals, sometimes generally referred to as
30 cattle in this application. The method comprises administering an anabolic implant composition which is a dual formulation comprising (i) an immediate-release formulation containing an anabolic agent, and

- 6 -

(ii) a controlled-release formulation containing an anabolic agent and a controlled-release agent. The immediate-release formulation and the controlled-release formulation cooperate in the cattle to effect the desired stimulation of growth and weight gain. Even though the dual
5 formulation may be administered as one composition by simultaneous administration of both (i) and (ii) above in one administering (injecting) device, or administered one formulation followed by the other in quick succession in whichever order the administrator prefers, the following description, for simplicity sake, describes the invention as
10 a single step simultaneous administration method.


The present invention concerns a method of stimulating increased rate of growth, greater amount of growth and greater feed efficiency in food animals which comprises providing to such animals biodegradable and non-biodegradable compressed tablets loaded with an
15 anabolic agent. The method of the present invention provides advantages over methods known in the art such as, *inter alia*, increased weight gain, a biodegradable or nonbiodegradable system, an implant system, the ability to mix tablets (pellets) containing different drugs and the ability to program the release rate (multiphasic release patterns).

20 In a preferred embodiment, administration of the growth promotant to food animals by the method of the invention is achieved by a single administration of the growth promotant loaded into compressed shapes such as, for example, tablets which release the active anabolic agent into the animal in a constant or pulsed manner and
25 eliminates the need for repetitive injections. Some of the tablets contain the active anabolic agent with no controlled-release agent, while the other tablets contain the active anabolic agent with a controlled-release agent, as described later in the Examples. Thus, the former acts as the immediate-release formulation while the latter acts as the controlled
30 formulation.

The anabolic agent used in the two formulations may be the same or different. Illustrative anabolic agents suitable for and useful as

- 7 -

growth promotants in the present invention include zeranol, estradiol and its derivatives such as, for example, estradiol benzoate, trenbolone acetate (Formula II, CAS Registry Number: 10161-34-9, available from Pharmacia & Upjohn Company, Kalamazoo, Michigan), somatotrophin
5 and its derivatives, testosterone and its derivatives such as, for example, testosterone propionate, salbutamol, progesterone, its derivatives and combinations thereof.

Formula II

In the immediate-release formulation, the anabolic agent may be
10 used as it is or optionally formulated with minor amounts of other materials such as, for example, diluents, excipients, tableting agents and the like that are suitable for insertion under the skin. Examples of some of these materials include lactose as a diluent, magnesium stearate as a lubricant, silica as a glidant and the like. For example, the commercially
15 available Ralgro® is formulated with lactose. Other diluent materials include, for example, mannitol, sorbitol, sucrose, dextrose, starches, hydrolyzed starches, and the like.

In the controlled-release formulation (also referred to as sustained-release formulation in this application), generally the
20 controlled-release agent is a polymer matrix. The polymeric matrix material must be biocompatible. The term biocompatible is defined as a polymeric material which is not toxic to an animal and is not carcinogenic. Whereas the matrix material is biodegradable, the polymeric material should degrade by bodily processes to products
25 readily disposable by the body and should not accumulate therein.

- 8 -

When the matrix is non-biodegradable, it is still biocompatible and may remain within the animal at the site of implantation indefinitely.

Suitable examples of polymeric matrix materials useful in the present invention include poly(D,L-lactide-co-glycolide) copolymer, ethyl

5 cellulose, methyl acrylate-methyl methacrylate copolymer, methylcellulose, hydroxyethyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethyl cellulose, and the like. As in the immediate-release formulation, the anabolic agent and the polymer matrix material in the controlled-release formulation may be optionally formulated
10 with minor amounts of other materials such as, for example, diluents, excipients, tableting agents and the like, that are suitable for insertion under the skin. Examples of some of these materials include lactose as a diluent, magnesium stearate as a lubricant, silica as a glidant and the like.

15 The implant is generally in the shape of a cylindrical tablet. The tablet will generally have a diameter of from about 2.0 mm to 6.0 mm and a length of from about 1.0 mm to about 4.0 mm. The implants for the controlled-release are generally prepared by a procedure wherein the active anabolic agent is mixed with the poly(D,L-lactide-co-glycolide)
20 copolymer or the ethyl cellulose together with the other optional materials and this is then compressed in the die of a tableting press as is known in the art. Suitable illustrative procedures to make such implants with biodegradable polymer and with non-biodegradable polymer are described later in this application.

25 The rate of release of the anabolic agent in the controlled-release formulation can be controlled by a variety of measures. With respect to the poly(D,L-lactide-co-glycolide) copolymer, the rate of degradation of the carrier matrix can be increased by decreasing the size and consequently the molecular weight of the polymer chains. Increasing
30 the amount of the active anabolic agent and consequently reducing the active copolymer weight ratio will increase rate of release. The incorporation of additional plasticizers and other excipients may even

- 9 -

speed up the degradation and release. Such modifications will be obvious to those skilled in the art.

The preparation of the implants containing a biodegradable polymer such as, for example, the poly(D,L-lactide-co-glycolide) copolymer, may be achieved utilizing any number of methods known in the art. An illustrative procedure is as follows. Preferably the anabolic active is first dissolved in a suitable solvent that will also solubilize, emulsify or disperse the poly(D,L-lactide-co-glycolide) copolymer. Suitable solvents include organic solvents such as acetone, chloroform, methylene chloride, other aromatic hydrocarbons, cyclic ethers, esters, alcohols and the like and mixtures thereof. The polymer matrix material is also dissolved or dispersed in the solvent and the emulsion or solution formed thereby may be mixed into a continuous phase. A surfactant may be added to the solution to prevent agglomeration.

The solvent is then removed, generally by the application of heat, the application of reduced pressure or both. The temperature employed is not critical but it should not be so high as to result in a degradation of either the active compound or the implant biodegradable matrix material. Once the solvent is removed, the solid dose implants may then be prepared using a standard tableting die press as is known in the art.

Preferably, the anabolic agent useful in the formulation of the present invention is zeranol. A commercially available formulation of zeranol is Ralgro® (from Schering-Plough Corporation, Terre Haute, Indiana) which additionally contains some lactose. The zeranol content in the present formulation is in an amount of from about 50 wt.% to 95 wt.% preferably from about 55 wt.% to about 85 wt.% and most preferably from about 60 wt.% to about 80 wt.%, based on the total weight of the implant composition (including both the immediate-release part and the controlled-release part).

The poly (D,L,-lactide-co-glycolide) copolymer is incorporated in the sustained-release formulation in amounts ranging from about 1.0

- 10 -

wt.% to about 10 wt.% and preferably from about 1.0 wt.% to about 5.0 wt.%. If ethyl cellulose is used as the agent in place of the poly(D,L-lactide-co-glycolide) copolymer, greater amounts may be used such as from about 1.0 wt.% to 8.0 wt.% and preferably from about 2.0 wt.% to about 7.0 wt.%.
5

The other optional materials may be added to the formulation according to the length of drug delivery desired, but for the most part these will be added in standard amounts as is known in the art. For example, a diluent or excipient may be added in amounts of from about 20wt.% to 40 wt.%, preferably in an amount of from about 25wt.% to 40 wt.%, and typically in amounts of from about 25 wt.% to 30 wt.%. Coloring dyes for foods, drugs & cosmetics ("FD & C"), and the like may be incorporated into the formulations in amounts of from 0.1 wt.% to 2.0 wt.% as is known in the art.
10

Implants containing non-biodegradable polymer such as, for example, ethyl cellulose, may be prepared by procedures known in the art. An illustrative procedure is as follows: The anabolic agent such as zeranol is mixed with a diluent such as, for example, lactose, and optionally a suitable dye in a planetary mixer. In a separate mixer, an aqueous dispersion of ethylcellulose commercially available as Aquacoat ECD-30® (available from FMC Corporation, Philadelphia, Pennsylvania) is mixed with a suitable plasticizer such as triacetin, or dibutyl sebacate, etc. The plasticized ethyl cellulose is then blended with the anabolic agent/lactose mixture and granulated. The granules are dried at a temperature of from about 50° c to 70° C until the formulation is characterized by a moisture level of from about 0.2 wt.% - 0.6 wt.% based on the total weight of the formulation. The dried granules are then sized through a sieve, such as, for example, the Fitzmill sieve or its equivalent, and then lubricated with an appropriate lubricant such as magnesium stearate and a glidant such as, for example, silicon dioxide. The granules are then compressed into pellets of the desired size and hardness.
15
20
25
30

- 11 -

Without being bound to any theory, it is believed that ethyl cellulose which is a pseudolatex matrix is distributed evenly throughout the wet mass. Upon drying, the matrix particles become finely blended with the active anabolic agent and the excipients. Compression in the
5 tablet die further condenses the ingredients together.

A heating or curing step is important as this seems to fuse or coalesce the ethyl cellulose particles forming a true matrix structure about the active. This results in the active anabolic agent/excipient blend being fully entrapped by the ethyl cellulose chains.

10 For the immediate-release formulation, compositions such as the commercially available zeranol product, such as, for example, Ralgro®, may be used and compressed into suitable size tablets. Any optional ingredients such as, for example, dye and the like, may be mixed in before compressing into tablets.

15 The inventive dual formulation is prepared by taking a certain number of thus-prepared tablets containing the controlled-release formulation and a certain number of thus-prepared immediate-release formulation (including Ralgro® which is zeranol plus lactose) tablets in the injection device. The number of each kind is determined based on
20 the total amount of zeranol one desires to inject into the animal. For comparison purposes, the dual formulation injection may be compared with injection of either the controlled formulation tablets alone or the zeranol tablets alone such that the total amount of zeranol would still match with the total zeranol in the inventive dual formulation. The
25 growth enhancement implant pellets are generally subcutaneously injected into the cattle, or other domesticated animal under the ear. After administration, water diffuses into the tablet from the tissue of the animal and is driven by hydration of the lactose and to a small extent by hydration of the anabolic agent. The dissolved active then diffuses out
30 of the matrix structure and into the animal's systemic circulation. As the EXAMPLES demonstrate, Applicants found that the inventive dual formulation tablets surprisingly resulted in a higher increase of growth

- 12 -

and weight gain in the test animals than either the controlled-release tablets alone or the zeranol tablets alone.

Another embodiment of the present invention discloses anabolic implant compositions and formulations for stimulating increased rate
5 of growth, greater amount of growth and greater feed efficiency in cattle. The inventive composition is a dual release formulation which comprises: (i) an immediate-release formulation containing an anabolic agent, and (ii) a controlled-release formulation containing an anabolic agent and a controlled-release agent, wherein the immediate-release
10 formulation and the controlled-release formulation cooperate to effect the desired stimulation of growth and weight gain. The types and examples of (i) and (ii) are described above.

A further embodiment of the present invention discloses a method of stimulating increased rate of growth, greater amount of
15 growth and greater feed efficiency in cattle, whose growth, weight gain and feed efficiency need to be improved, by administering to said cattle an anabolic implant composition which is a dual release formulation which comprises: (i) an immediate-release formulation containing an anabolic agent, and (ii) a controlled-release formulation containing an
20 anabolic agent and a controlled-release agent, wherein the immediate-release formulation and the controlled-release formulation cooperate to effect the desired stimulation of growth and weight gain. The types and examples of (i) and (ii) are described above.

A still further embodiment of the present invention concerns a
25 method for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in an animal. The method comprises: preparing an immediate-release formulation comprising an anabolic agent such as, for example, the agents described above, in a shaped object suitable for loading into a device such as, for example, pellets, tablets
30 and the like, which device is suitable for administration of said shaped object into the animal (such as, for example, the pistol described earlier); preparing a controlled-release formulation containing an anabolic agent

- 13 -

and a controlled-release agent, in a shaped object similar to above and suitable for loading into the device in step (a), wherein said anabolic agent in step (a) and said anabolic agent in step (b) may be the same or different; loading the device with the shapely object in step (a) and the shapely object in step (b) in a ratio such that the total anabolic agent is in the 50-95 weight percent range based on the combined weight of the two formulations (i.e. the formulation in step (a) and the formulation in step (b)); and administering the shaped objects into the animal, wherein said immediate-release formulation and said controlled-release formulation cooperate to effect the desired stimulation. Suitable controlled agents and methods for making the formulations are described above.

The following EXAMPLES are provided to more fully describe how to make and use the implants of the present invention, as well as to demonstrate the superior results attained thereby. It should be noted however that the examples are for illustrative purposes only and that minor changes or variations may be made in the amounts and/or methods that are not covered therein. It should also be noted that to the extent any such changes or variations that do not materially alter the composition or effects of the final product are deemed as falling within the spirit and scope of the present invention as later recited in the claims.

EXAMPLES

25

EXAMPLE 1: Comparison of Weight Gain with Zeranol as Immediate-release Formulation to a Formulation Containing Zeranol as Controlled-release Formulation: The following zeranol matrix base formulations were prepared to compare controlled-release formulations containing zeranol with Ralgro and a placebo (an ineffective control). As stated earlier, Ralgro is a commercially available product of zeranol and lactose.

- 14 -

FormulationComposition

	A	Controlled-release Formulation: zeranol/poly(D,L-lactide-co-glycolide copolymer; 50:50 wt%) (180 mg total zeranol)
5	B	Controlled-release Formulation: zeranol/ethyl cellulose (50:50 wt%, 180 mg total zeranol)
	C	Ralgro® (36 mg zeranol)
	D	Placebo: no Zeranol

10 The implants were prepared as follows. For formulation A, the poly (D,L-lactide-co-glycolide 50:50, 3.991 g) was placed in an Erlenmeyer flask and dissolved in 50 grams of ethyl acetate. Separately, the zeranol and lactose (26.606 g) were mixed together dry in a mortar to which the FD & C coloring dyes (0.44 g) were added. The solvent comprising D,L-

15 lactide-co-glycolide and ethyl acetate was then added to the zeranol/dye/lactose mixture. The composition was then heated to 40-45°C. to complete dryness and granulated and sized through a 25 mesh screen. A Cab-O-Sil® silica glidant (0.665 g) was added along with magnesium stearate (1.33 g) which was added as a lubricant. The

20 compositions were then compressed in a tableting die to obtain solid implants (26.606 mg each implant) with a hardness of 12-20 Strong Cobb units. Formulation B was prepared in a similar manner using ethyl cellulose as the polymer matrix and Aquacoat ECD-30 instead of ethyl acetate. For formulation C, Ralgro® was made into similar size tablets

25 using procedures known in the art. And formulation D, the control with no zeranol was made into tablets similar to in formulation C.

 The implants were administered to twenty (20) steers subcutaneously under the ear. In order to properly compare the formulations of the present invention with those of the prior art,

30 formulation C was administered twice, once at day 0 and again at day 70, each dose containing 36 mg of zeranol. Each steer was weighed at selected time periods during its development and the average body

- 15 -

weight for each group given a particular formulation A to D was calculated for each date and are as follows:

Table 1

Treatment	Day	Day	Day	Day	Day	Day	Day	Day	Day
	0	28	56	70	84	112	140	168	182
5	A	339	423	483	544	562	616	693	765
	B	337	426	492	558	568	631	701	780
	C	339	431	506	562	578	644	716	812
	D	342	420	473	531	536	593	645	709
10									

The results show that the weight gain with either controlled-release formulation (A or B) is slightly lower than or, at best, statistically equivalent to that of the Ralgro® re-implant program of formulation C.

Example 2: Comparison of Weight Gain with Inventive Dual Formulation versus Weight Gain with Immediate Formulation alone, or with Controlled Formulation alone: The effects of implanting the dual immediate-release/controlled-release pellets of the present invention on weight and growth gain were studied and compared with zeranol (as Ralgro®) alone, with controlled-release formulation alone and with a non-effective placebo control. That could be done by replacing certain controlled-release tablets of Example 1 with Ralgro® tablet(s). The administered dosages were as follows. The total weight administered is shown in brackets.

- 16 -

	<u>Formulation</u>	<u>Composition</u>
	E	Placebo control; no zeranol
	F	Ralgro® (36 mg zeranol; 3 pellets 12 mg each)
5	G	Zeranol immediate-release (1 pellet of 18 mg zeranol) + Zeranol controlled-release-poly (D,L-lactide-co-glycoside) (80 mg zeranol;
4		pellets of 20 mg each) [98 mg total zeranol]
10	H	Zeranol immediate-release (1 pellet of 18 mg zeranol) + Zeranol controlled-release /poly (D,L-lactide-co-glycolide) (160 mg zeranol;
		8 pellets of 20 mg zeranol each) [178 mg total zeranol]
	I	Zeranol immediate-release (1 pellet of 18 mg zeranol) + Zeranol controlled-release /ethyl cellulose (160 mg zeranol; 8 pellets of 20
		mg zeranol each) [178 mg total zeranol]
15	J	Zeranol immediate-release (1 pellet of 18 mg zeranol) + Zeranol controlled-release /ethyl cellulose (80 mg zeranol; 4 pellets of 20
		mg zeranol each) [98 mg zeranol total]

As can be seen, to prepare the inventive dual formulations H and I, one zeranol immediate-release pellet and 8 zeranol controlled-release pellets were taken in the device. Similarly, to prepare the inventive dual formulations G and J containing just half the amount of the controlled-release formulation, one zeranol immediate-release pellet and 4 controlled-release pellets were taken in the device. The immediate-release pellets and control release pellets were formulated as in Example 1 and administered to six groups of cattle in a similar fashion, i.e., subcutaneously under the ear. Again, in order to compare the improved formulations with the prescriptions currently followed in the veterinary art, formulation F was administered twice, once (36 mg) at day 0 and again (36 mg) at day 70. Each steer was weighed at different intervals during its development and the average weight for each group given a particular formulation was averaged for each date. The formulations and average weight gain results for each are as follows:

- 17 -

Table 2

5	Treatment Formulation	<u>Average Body Weight (in kilograms)</u>						
		Day (-1)	Day 0	Day 28	Day 56	Day 84	Day 112	Day 140
10	E	309	303	352	389	425	461	491
	F	309	300	356	398	435	477	511
	G	308	301	354	401	444	485	525
	H	309	302	358	404	445	485	525
	I	309	302	357	408	451	494	533
	J	309	302	356	402	443	481	518

15 As is evidenced by the results shown for formulations G-J,
superior growth and weight gains were observed with the inventive
dual release formulations. Thus, when one (out of nine) of the
controlled-release formulation pellets was replaced with one
immediate-release pellet (formulations H and I), the weight gain became
20 significantly higher than the results observed following the standard
immediate re-implant program (formulation F) above. Such
improvement was also noticed even when the controlled-release
fraction was reduced by half (from 160 to 80 mg or 8 to 4 pellets) as
shown in formulations G and J.

CLAIMS

What is claimed is:

1. An anabolic implant composition for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in cattle,
5 said composition comprising: (i) an immediate-release formulation comprising an anabolic agent, and (ii) a controlled-release formulation comprising an anabolic agent and a controlled-release agent, wherein said immediate-release formulation and said controlled-release formulation cooperate to effect said stimulation.
- 10 2. The implant composition of claim 1, wherein said immediate-release formulation and said controlled-release formulation are present respectively in a weight ratio range 1:2 to 1:25 in said composition.
3. The implant composition of claim 1, wherein said immediate-release formulation and said controlled-release formulation are present
15 respectively in a weight ratio range 1:2 to 1:10 in said composition.
4. The implant composition of claim 1, wherein said immediate-release formulation and said controlled-release formulation are present respectively in a weight ratio range 1:3 to 1:8 in said composition.
5. The implant composition of claim 1, wherein said composition is
20 subcutaneously injectable in said cattle.
6. The implant composition of claim 1, wherein said immediate-release formulation and said controlled-release formulation contain the same anabolic agent.
7. The implant composition of claim 1, wherein said immediate-
25 release formulation and said controlled-release formulation contain different anabolic agents.
8. The implant composition of claim 1, wherein said anabolic agent is selected from the group consisting of zeranol, estradiol, estradiol benzoate, trenbolone, trenbolone acetate, somatotrophin, testosterone, testosterone propionate, salbutamol, progesterone, and combinations,
30 salts and derivatives thereof.

- 19 -

9. The implant composition of claim 8, wherein said anabolic agent is zeranol.
10. The implant composition of claim 8, wherein said anabolic agent is trenbolone acetate.
- 5 11. The implant composition of claim 9, wherein said zeranol is the anabolic agent in both said immediate-release formulation and said controlled-release formulation and comprises from about 50 wt.% to about 95 wt.% of said composition based on a total weight percentage basis.
- 10 12. The implant composition of claim 9, wherein said zeranol is the anabolic agent in both said immediate-release formulation and said controlled-release formulation and comprises from about 60 wt.% to about 80 wt % of said composition.
13. The implant composition of claim 1, wherein said immediate-release formulation additionally contains a diluent.
- 15 14. The implant composition of claim 13, wherein said diluent is selected from the group consisting of lactose, mannitol, sorbitol, sucrose, dextrose, starches, hydrolyzed starches, and combinations thereof.
15. The implant composition of claim 14, wherein said diluent is lactose.
- 20 16. The implant composition of claim 1, wherein said controlled-release agent is selected from the group consisting of poly(D,L-lactide-co-glycolide), ethyl cellulose, methyl acrylate-methyl methacrylate copolymer, methyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and combinations thereof.
- 25 17. The implant composition of claim 16, wherein said controlled-release agent is poly(D,L-lactide-co-glycolide).
18. The implant composition of claim 16, wherein said controlled-release agent is ethyl cellulose.
- 30

- 20 -

19. The implant composition of claim 1, wherein said controlled-release agent comprises from about 1.0 wt.% to about 8.0 wt.% based on the total weight of said implant composition.
20. The implant composition of claim 1, further comprising a
5 bulking agent, binder, excipient, tableting agent, colorant and combinations thereof.
21. A method for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in cattle, comprising the administration of an anabolic implant composition to said cattle which
10 composition comprises: (i) an immediate-release formulation comprising an anabolic agent, and (ii) a controlled-release formulation comprising an anabolic agent and a controlled-release agent, wherein said immediate-release formulation and said controlled-release formulation cooperate to effect said stimulation.
- 15 22. The method of claim 21, wherein said immediate-release formulation and said controlled-release formulation are present in a weight ratio 1:25 in said composition.
23. The method of claim 21, wherein said administration comprises subcutaneously injecting said composition into said cattle.
- 20 24. The method of claim 21, wherein said immediate-release formulation and said controlled-release formulation contain the same anabolic agent.
25. The method of claim 21, wherein said immediate-release formulation and said controlled-release formulation contain different
25 anabolic agents.
26. The method of claim 21, wherein said anabolic agent is selected from the group consisting of zeranol, estradiol, estradiol benzoate, trenbolone, trenbolone acetate, somatotrophin, testosterone, testosterone propionate, salbutamol, progesterone, and combinations,
30 salts and derivatives thereof.
27. The method of claim 26, wherein said anabolic agent is zeranol.

- 21 -

28. The method of claim 27, wherein said zeranol is the anabolic agent in both said immediate-release formulation and said controlled-release formulation and comprises from about 50 wt.% to about 95 wt.% of said composition.
- 5 29. The method of claim 27, wherein zeranol is the anabolic agent in both said immediate-release formulation and said controlled-release formulation and comprises from about 60 wt.% to about 80 wt % of said composition.
30. The method of claim 21, wherein said immediate-release
10 formulation additionally contains a diluent.
31. The method of claim 30, wherein said diluent is selected from the group consisting of lactose, mannitol, sorbitol, sucrose, dextrose, starches, hydrolyzed starches, and combinations thereof.
32. The method of claim 31, wherein said diluent is lactose.
- 15 33. The method of claim 21, wherein said controlled-release agent is selected from the group consisting of poly(D,L-lactide-co-glycolide), ethyl cellulose, methyl acrylate-methyl methacrylate copolymer, methyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and combinations thereof.
- 20 34. The method of claim 33 , wherein said controlled-release agent is poly(D,L-lactide-co-glycolide).
35. The method of claim 33, wherein said controlled-release agent is ethyl cellulose.
36. The method of claim 21, further comprising a bulking agent,
25 binder, tableting agent, excipient, colorant and combinations thereof.
37. A method for stimulating increased rate of growth, greater amount of growth and greater feed efficiency in an animal, said process comprising:
- 30 (a) preparing an immediate-release formulation comprising an anabolic agent, in a first shaped object suitable for loading into a device which device is suitable for administration of said shaped object into the animal;

- 22 -

(b) preparing a controlled-release formulation comprising an anabolic agent and a controlled-release agent, in a second shaped object suitable for loading into said device in step (a), wherein said anabolic agent in step (a) and said anabolic agent in step (b) may be the same or
5 different,

(c) loading said device with said first shaped object and said second shaped object in a ratio such that the total anabolic agent is in the 50-95 weight percent range based on the combined weight of said formulation in step (a) and said formulation in step (b); and

10 (d) administering said shaped objects into the animal, wherein said immediate-release formulation and said controlled-release formulation cooperate to effect the stimulation.

38. The method of claim 37, wherein said anabolic agent in step 9a) and step (b) is the same and is zeranol.

15 39. The method of claim 37, wherein said controlled-release agent in step (b) is poly(D,L-lactide-co-glycolide), ethyl cellulose, methyl acrylate-methyl methacrylate copolymer, methyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and combinations thereof.

20 40. The method of claim 37, further containing lactose in step (a), step (b) or both.

41. The method of claim 37, wherein said first shaped object, or said second shaped object, or both is a tablet.

25 42. The method of claim 37, wherein said first shaped object, said second shaped object, or both is a pellet.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : A61K 9/00, A61P 5/00		A3	(11) International Publication Number: WO 00/25743
			(43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/23993			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 2 November 1999 (02.11.99)			
(30) Priority Data: 09/185,944 4 November 1998 (04.11.98) US			
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
(72) Inventors: SHIH, Chung; 2798 E. Amberwick Lane, Sandy, UT 84093 (US). KENNEDY, Thomas, J.; 5492 Kennedy Drive, Waunakee, WI 53597 (US). KNIGHT, Peter, James; 1826 Gary Road, Warren, NJ 08886 (US). ROBINS, Daniel, S.; Apartment 3B, 77 East 12th Street, New York, NY 10003-5003 (US). SHAO, Zezhi, Jesse; 68 Patriot Hill Drive, Basking Ridge, NJ 07920 (US).			
(74) Agents: KALYANARAMAN, Palaiyur, S. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			Published <i>With international search report.</i>
(88) Date of publication of the international search report: 24 August 2000 (24.08.00)			
(54) Title: IMPROVED GROWTH STIMULANT COMPOSITIONS			
(57) Abstract An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23993

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/00 A61P5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 4 670 249 A (IVY RICHARD E ET AL) 2 June 1987 (1987-06-02)</p> <p>column 1, line 56 -column 2, line 20 column 3, line 61 -column 4, line 2 column 4, line 21 - line 29; claims</p> <p style="text-align: center;">-/-</p>	<p>1,5,7-9, 13-15, 20,21, 23, 25-27, 30-32,36</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23993

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>US 5 874 098 A (SPURLIN STANFORD R ET AL) 23 February 1999 (1999-02-23)</p> <p>column 3, line 8 - line 47 column 4, line 26 - line 32 column 5, line 26 - line 36; claims 1,3,8,10; examples</p>	<p>1,5, 7-13,20, 21,23, 25,26, 30,36, 37,39, 41,42</p>
X	<p>O'CALLAGHAN, D. ET AL: "Effects of long acting and short acting estradiol implants on growth rate and carcass weight of steers" VET. REC. (1986), 119(17), 427-9 , XP000907270 abstract page 427, column 1, last paragraph -page 427, column 2, paragraph 1 page 427, column 2, paragraph 3 -page 427, column 2, paragraph 4 page 428, column 1, paragraph 2 -page 428, column 1, paragraph 3</p>	<p>1,5,7,8, 10, 21-23, 25,26</p>
A	<p>US 5 219 572 A (SIVARAMAKRISHNAN KALLIDAIKURIC ET AL) 15 June 1993 (1993-06-15) column 2, line 29 - line 57 column 3, line 31 - line 36 column 3, line 51 - line 61 column 4, line 15 - line 20 column 4, line 39 - line 52 column 6, line 3 - line 33 claims; example 1</p>	<p>1-36</p>
A	<p>GB 2 167 662 A (CRB VIRBAC SARL) 4 June 1986 (1986-06-04) page 1, line 5 - line 9 page 1, line 32 - line 39 page 1, line 55 -page 2, line 4; claims; examples 1-7</p>	<p>1-36</p>
A	<p>US 5 747 060 A (CHASIN MARK ET AL) 5 May 1998 (1998-05-05) column 4, line 11 - line 28 column 7, line 58 - line 66; claims 1-5,7,8</p>	<p>1-36</p>

INTERNATIONAL SEARCH REPORT

I. .national application No.

PCT/US 99/ 23993

Box I Observations where certain claim were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21-42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-42 relate to a compound, defined by reference to a desirable characteristic or property, namely an "anabolic agent". The term "anabolic agent" as used in the present independent claims 1, 27, 31 and in dependent claims 6-12, 26-29, 38 defines the active agent by its pharmacological effect. However, a compound cannot be sufficiently characterised by its pharmacological effect as it is done by an expression like "anabolic agent", because it is impossible to know which substances are encompassed in this expression. Thus the present independent claims 1, 27, 31 and in dependent claims 6-12, 26-29, 38 are not clear, because the pharmacological definition is vague and renders thus the scope of said claims obscure.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for the concept of "anabolic agent" and those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in claims 8 and 26.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members


International Application No

PCT/US 99/23993

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4670249 A	02-06-1987	AT 55901 T	15-09-1990
		AU 585597 B	22-06-1989
		AU 5609786 A	16-10-1986
		CA 1287577 A	13-08-1991
		DE 3673690 D	04-10-1990
		EP 0201219 A	12-11-1986
		JP 2008324 C	11-01-1996
		JP 7025703 B	22-03-1995
		JP 61251628 A	08-11-1986
		MX 171169 B	06-10-1993
		NZ 215790 A	29-09-1988
		NZ 225910 A	27-01-1989
		ZA 8602782 A	26-11-1986
US 5874098 A	23-02-1999	NONE	
US 5219572 A	15-06-1993	AT 90203 T	15-06-1993
		AU 634529 B	25-02-1993
		AU 5279290 A	22-10-1990
		DE 69001898 D	15-07-1993
		DE 69001898 T	23-09-1993
		DK 463061 T	12-07-1993
		EP 0463061 A	02-01-1992
		JP 4504122 T	23-07-1992
		NO 913649 A	16-09-1991
		WO 9011070 A	04-10-1990
GB 2167662 A	04-06-1986	FR 2573307 A	23-05-1986
		AU 585280 B	15-06-1989
		AU 4998285 A	29-05-1986
		BE 903610 A	09-05-1986
		DE 3539408 A	05-06-1986
		IT 1188195 B	07-01-1988
		NL 8503227 A	16-06-1986
		NZ 214179 A	28-06-1989
		ZA 8508486 A	25-06-1986
US 5747060 A	05-05-1998	NONE	

THIS PAGE BLANK (USPTO)

Figure 1. Estradiol Levels in Calves



THIS PAGE BLANK (USPTO)